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Tumor microenvironmentTumor cell plasticity is an event that has been observed in several malignancies. In fact, most of the
solid tumors are characterized by cellular heterogeneity and undergo constant changes as the tumor
develops. The increased plasticity displayed by these cells allows them to acquire additional
properties, enabling epithelial-mesenchymal transitions, dedifferentiation and the acquisition of
stem cell-like properties. Here we discuss the particular importance of an inﬂammatory microenvi-
ronment for the bidirectional control of cellular plasticity and the potential for therapeutic
intervention.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
A tumor originates from the clonal expansion of a single cell
that has acquired the ability of extensive self-renewal and
unlimited proliferation. Surprisingly however, a tumor is never
composed of completely identical cells; in fact most of the solid
malignancies are characterized by heterogeneity and are undergo-
ing constant changes as the tumor develops. Importantly, it is not
only the tumor cell that is highly plastic, but also the tumor
microenvironment. The bidirectional regulation that exists
between tumor cells and their environment is the most important
determinant of tumor plasticity. Since tumors undergo continuous
alterations as they progress, the tumor site can be considered as a
place where a never-ending deconstruction and reconstruction
takes place and the tumor itself is the architect.
This extreme plasticity which characterizes malignant growth
can be induced both by tumor cell-intrinsic- and extrinsic factors.
Among the cell-intrinsic factors that can induce a highly plastic
phenotype are mutations in oncogenes and tumor suppressors.
These mutations can alter not only the morphology, metabolic
state, proliferative capacity or the motility of the cell, but also
determine its interaction with the other cells in its vicinity. There-
fore, the tumor cell has the ability to alter its microenvironment by
direct cell–cell contact or by release of paracrine factors. This way
the tumor cell is able to alter the tumor composition by inducing
the formation of new blood vessels, recruiting new cell types and
restructuring the extracellular matrix. On the other hand, thetumor microenvironment has a very profound effect on the tumor
cell plasticity as well. Depending on the environment in which the
tumor cell resides it can adopt different phenotypes and behaviors
contributing to intratumoral heterogeneity. However, if the cell
leaves its established microenvironment or the environment
changes, the tumor cell can adopt completely new properties.
Two important mechanisms controlling tumor cell plasticity
signiﬁcantly contribute both to tumor initiation and progression.
During tumor initiation, dedifferentiation and acquisition of stem
cell-like characteristics increases the number of tumor-initiating
cells and favors self-renewal. At later stages, these stem cell-like
cells are suggested to play an important role in therapy-resistance
and metastases. Similarly, during tumor progression, the induction
of epithelial-mesenchymal plasticity (EMP), including both epithe-
lial to mesenchymal – and mesenchymal to epithelial transition,
enables tumor cells with the ability to migrate to distant organs
and establish metastases. Both EMP and dedifferentiation can
therefore be considered as distinct types of tumor-plasticity that
result in a population of tumor cells that contribute to a more
aggressive phenotype. Although EMP and dedifferentiation are
independently controlled events they also share certain common
triggers and regulatory mechanisms.
2. On the move
One important phenomenon in tumor cell plasticity is the
ability of the epithelial tumor cells to acquire a more mesenchymal
phenotype and when needed return to the original epithelial state.
By hijacking the mechanisms of embryonic developmental
programs, epithelial to mesenchymal transition (EMT) and
Table 1
Commonly used EMT markers in cancer. TGF-b: transforming growth factor b; aSMA:
alfa smooth muscle actin; MMP: matrix metalloproteinase; NF-jB: nuclear factor
kappa B; Sox10: SRY (sex determining region Y) box 10; SMAD: contraction of Sma
and Mad (Mothers against decapentaplegic); PI3K: phosphatidylinositol 3-kinase;
AKT: protein kinase B.
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capabilities to invade surrounding tissues, migrate to- and colonize
distant organs. The ability of the tumor cells to readily transit
between epithelial- and mesenchymal states can be referred to
as epithelial-mesenchymal plasticity [1].
Epithelial and mesenchymal cells are recognized by their
unique morphology and tissue organization. They differ in several
important aspects such as polarity and cell–cell contacts. In
contrast to epithelial cells, which usually form continuous and
cohesive sheets that line the cavities throughout the body, mesen-
chymal cells embed themselves inside the extracellular matrix
(ECM) and rarely establish tight junctions with surrounding cells.
During embryonic morphogenesis cells need to migrate to adjacent
tissues and even travel long distances inside the embryo. This
process is only possible due to the activation of the epithelial to
mesenchymal transition program, which allows stationary epithe-
lial cells to become dynamic and to move during the developmen-
tal morphogenesis [2,3]. In summary, loss of cell junctions and
apico-basal polarity together with the acquisition of mobility are
the steps which epithelial cells are submitted during EMT.
Importantly, when those cells reach their ﬁnal destination the
EMT program must be reversed, with cells returning to their origi-
nal epithelial phenotype, undergoing mesenchymal to epithelial
transition, or MET. Only then, they can start to proliferate and give
rise to different tissues and organs [1,4].
Intriguingly, the EMT and MET process are also found in
non-homeostatic situations. Research on this topic suggests that
EMT and MET are restarted in many diseases, with a fully activated
pattern in malignant processes and its dissemination to distant
organ – metastasis [5–7].
EMT is often adopted by cancer cells, providing them with a
highly invasive and migratory phenotype. The contribution of
EMT in promoting cancer cell invasion and metastasis has been
documented in many carcinoma types, including those arising in
colon, ovary, breast, lung, prostate and head and neck [4,8,9]. It
is during EMT – and later during MET – that cancer cells invade
the surrounding tissue, enter the microvasculature (intravasation),
translocate through the bloodstream, exit from the blood vessels
(extravasation), survive in a different microenvironment and
ﬁnally colonize it, forming a secondary tumor site, the metastasis
[10,11].
To initiate this process the epithelial tumor cells must pass
through important molecular changes. Genes encoding cell-
junction proteins, such as E-cadherin, alpha-catenin and gamma-
catenin are downregulated. Among them, E-cadherin is regarded
as the main marker of the epithelial state [2,3]. E-cadherin
transcriptional repression, methylation, protein phosphorylation
and degradation have been already observed in response to EMT-
inducing signals by several groups [12–17]. While E-cadherin
expression is lost, the level of the mesenchymal-speciﬁc marker,
vimentin, increases, due to the switch of cytokeratin to vimentin
ﬁlaments (Table 1 lists some of the most common markers used
to deﬁne EMT in tumors).
It is generally accepted that EMT is a prerequisite for invasion
and metastatic dissemination, however distant metastases gener-
ally present an epithelial morphology [18,19]. But why would
tumor cells revert to an epithelial phenotype to fully establish a
macrometastasis? In vitro studies showed that on reason might
be the EMT-associated growth arrest, and since colonization of
the metastatic site demands a robust tumor cell proliferation,
reversion of EMT might provide growth advantages [20,21].
Although not universally accepted in cancer research, the presence
of a mesenchymal to epithelial transition has been elegantly sup-
ported in vivo by recent studies. Using a spontaneous squamous
cell carcinoma model in mice overexpressing skin-speciﬁc Twist-
1, Tsai et al. raised the possibility that tumor dormancy could bedue to the inability of disseminated tumor cells to revert the
EMT status and proliferate [22]. Moreover, Gao and colleagues,
demonstrated that versican knockdown in bone marrow cells sig-
niﬁcantly impaired lung metastases in vivo, without impacting
their recruitment to the lungs or altering the immune microenvi-
ronment. Versican, an extracellular matrix proteoglycan, stimu-
lated mesenchymal-epithelial transition of metastatic tumor cells
by attenuating phospho-Smad2 levels, which resulted in elevated
cell proliferation and accelerated metastases [23]. Consistently
with both works, Ocaña et al. showed that downregulation of an
EMT marker, Prrxl in human breast cancer cells was necessary
for effective lung metastasis colonization [24].
It is necessary to point out that induction of EMP in cancer cells
is not necessarily an intrinsic phenomenon during tumor
progression, yet, it has been suggested as a response to extracellu-
lar signals from the tumor microenvironment [25–32]. Several
ligands activate and maintain cancer cell plasticity, either in auto-
crine or paracrine manners. TGF-b signaling appears to be one of
the major inducers of plasticity and EMT during embryonic devel-
opment and cancer progression [33,34] TGF-b signaling has been
demonstrated to result directly in the epigenetic regulation of
downstream target genes. SMAD2 and SMAD3 associate with cer-
tain epigenetic regulators, such as TRIM33, which displace repres-
sive histone modiﬁcations, creating a poised chromatin structure
that can be accessed by transcriptional regulators [35] The EMT
transcription factor Snail represses the expression of E-cadherin
and thereby confers a ﬁbroblast-like behavior onto epithelial cells
that includes increased motility. This process occurs at the invasive
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associated macrophages (TAMs) takes place. An elegant study by
Wu et al. links these events by demonstrating that TAMs-derived
TNF-a via NF-jB leads to the stabilization of Snail, which is other-
wise a highly unstable protein. Knockdown of Snail expression
inhibits inﬂammation-induced breast cancer cell migration and
invasion in vitro and metastasis in vivo, suggesting that EMT is a
dynamic process controlled by an inﬂammatory microenvironment
[36,37].
The importance of a NF-jB-dependent inﬂammatory microen-
vironment for induction of EMT, enabling invasion and lymph node
metastasis was recently demonstrated in a model of carcinogen-
induced colorectal tumorigenesis [38]. Loss of p53 in the intestinal
epithelial cells leads to a change in the composition of tight
junctions and expression of mucins, which impairs the intestinal
epithelial barrier resulting in a chain of events that promote tumor
progression. As a consequence of the increased intestinal
permeability and enhanced delivery of bacterial products, intesti-
nal epithelial cells (IEC) activate inﬂammatory NF-jB signaling
and start to produce diverse chemokines. These chemokines recruit
myeloid cells to the tumor site, where they produce several NF-jB-
dependent pro-tumorigenic cytokines. Moreover, NF-jB activation
in IEC controls expression of Twist, which is essential for the induc-
tion of EMT (Fig. 1). Interestingly, deregulation of miR-34 that is
also controlled by p53 may further contribute to the invasive phe-
notype. MiR-34 suppression can be mediated by the inﬂammatory
tumor microenvironment via an IL-6/STAT3 loop [6].
Intriguingly, in some cases epithelial-mesenchymal plasticity is
closely associated with the acquisition of stem cell-like character-
istics. Human basal breast cancer cells are highly plastic and can
revert from a non-cancer stem cell (CSC) state to a cancer stem cell
state by upregulating the EMT transcription factor Zeb1. Interest-
ingly, the promoter region of Zeb1 is in a bivalent state in the
non-CSC population and therefore it can readily switch to an active
conﬁguration in response to stromal TGFb [39]. Under normal cir-
cumstances the expression of Zeb1 is controlled by the miRNA-200
family. Downregulation of miRNA-200 members, which is often
the case in many cancers, induces EMT and very importantly a
cancer stem cell phenotype [40]. Similar bidirectional negative
feed-back loop exists between Snail and mir-34 [41] and mir-34
has been also shown to suppress sternness [42,43]. On theDedifferentiation
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Fig. 1. NF-jB signaling exerted effects. High wnt-activity and concomitant NF-jB a
Simultaneously, NF-jB-dependent inﬂammatory microenvironment induces EMT promocontrary, evidence can be also found that it is the epithelial
phenotype that is required for the cell to acquire stem cell
functions. This is supported by the fact that generation of induced
pluripotent stem cells (iPCSs) from mouse embryonic ﬁbroblast
requires the transition to the epithelial state at the initial phase
of the reprogramming process and is orchestrated by BMP signal-
ing [44]. Similarly, downregulation of potent EMT inducers is asso-
ciated not only with the acquisition of an epithelial- but also- of a
stem cell phenotype [24,45]. Irrespectively of the question if it is
the epithelial or mesenchymal state that is associated with the
stem cell phenotype it is very likely that cancer cells can readily
switch between these states in response to external stimuli, which
might help them to effectively adopt to various environments.
3. Catching stemness
Most cancers arise by the step-wise accumulation of genetic
and epigenetic hits in speciﬁc genes that endow the mutated cell
with growth advantage. When aberrant genetic changes are
introduced into a stem cell it is more likely that these genetic
and epigenetic alterations will lead to tumor development. Stem
cells are long-lived and self-renewing cells and thus have the abil-
ity to accumulate and propagate such mutations and therefore are
good candidates for the cell of origin in many tumors. Studies using
genetically engineered mice provide ﬁrm evidence for the exis-
tence and importance of cancer stem cells in tumor initiation
and growth. Alteration in the Wnt signaling by mutations in APC
or CTNNB represents one of the earliest steps of colorectal carcino-
genesis. Introduction of a stabilized b-catenin allele or deletion of
Apc in intestinal stem cells (ISCs), leads to rapid tumor develop-
ment and provides evidence for the role of ISCs in tumor initiation
[46–50]. Moreover, Schepers and colleagues have shown that stem
cells contribute not only to the initial stages of tumor develop-
ment, but actively participate in the maintenance of the tumor
[50].
The tumor microenvironment can signiﬁcantly contribute to
stemness by activating or expanding the stem cell pool. Inﬂamma-
tion is known to increase the number-of wnt-active and tumor
initiating cells [51], therefore inﬂammatory conditions in the
tumor microenvironment might enhance tumor initiation by an
effect on the stem cell compartment. Inﬂammation induces theEMT
NF-κB
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B
ctivation induces dedifferentiation and acquisition of stem cell-like properties.
ting invasion and lymph node metastasis.
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Akt mediated phosphorylation and nuclear translocation of b-
catenin [52]. Phosphorylation of b-catenin by Akt probably governs
the activation of the of the stem cell compartment [53]. Moreover,
Lgr5 expression levels are increased in patients with ulcerative
colitis and Crohn’s disease [52].
However, stemness might be not a ﬁxed state of the cell and a
scenario in which cells can enter and leave the CSC-like state
(depending on their niche and environmental signals) is conceiv-
able. If the acquisition of the stem cell fate was a dynamic and
reversible process it is unlikely to be mediated solely by irrevers-
ible genetic changes such as mutations. Most probably ﬂexible
mechanisms such as epigenetic regulation of the gene expression
are dominant determinants of the cell stemness (Fig. 2). Therefore,
we suggest that, if exposed to certain environmental stimuli, even
differentiated cells can interconvert into a stem cell-like state
during a neoplastic process. Differentiated cells can regain self-
renewing and multipotent properties and thus can behave as
cancer stem cells. Recently, we have shown that differentiated
enterocytes can regain stem cell like characteristics and initiate
intestinal tumorigenesis in vivo. Interestingly, this phenomenon
was dependent on high wnt activity and concomitant NF-jB
activation, suggesting that inﬂammatory conditions in the tumor
may not only expand the stem cell pool, but also induce dediffer-
entiation and acquisition of stem cell like properties (Fig. 1) [54].
Importantly, in mixed lineage leukemia it is NF-jB activity, which
is required to maintain the aberrant histone modiﬁcations and the
induced stem cell program, suggesting that inﬂammatory
conditions regulate stem cell fate via epigenetic reprogramming,
most likely in cooperation with genetic changes in important
tumor suppressor and oncogenes (Fig. 2) [55].In
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Fig. 2. Tumor plasticity. EMP, dedifferentiation, transdifferentiation and cell fusion can
tumorigenesis. EMP enhances invasion, and metastatic dissemination. Dedifferentiation o
Transdifferentiation causes one cell type to interconvert into a different cell type and cel
All process share some common characteristics and similar regulatory mechanisms. The t
in most important tumor suppressors and oncogenes, epigenetic modiﬁcations and the inAnother argument in the support of the reversibility of the
differentiated state is the fact that the generation of induced plu-
ripotent stem cells does not require genetic changes and it can
be induced by the ectopic expression of a small number of tran-
scription factors [56]. The embryonic reprogramming factor Oct4
is expressed in many cancers and expression of Oct4 promotes
melanoma cell dedifferentiation and acquisition of a stem cell like
fate by inducing the expression of other embryonic transcription
factors such as Nanog and Klf4. Interestingly, Oct4 expression is
again regulated by the microenvironment as hypoxia strongly ele-
vates Oct4 levels providing a possible explanation how hypoxia
can induce a more aggressive phenotype [57].
Considering the major effect of the tumor microenvironment on
dedifferentiation, the particular niche in which the tumor cell
resides in might be one of the most important determinants of
its stemness. In colorectal tumors stromal cells and vessels are
not equally distributed and tumor cells located at the stroma-rich
regions of the tumors might therefore receive more signals that
direct them toward a stem cell-like state than tumor cells that
are located at stroma-poor regions. Cancer-associated ﬁbroblasts
(CAFs) which are enriched at the invasion fronts of colorectal
tumors produce HGF, OPN and SDF-1 to activate the c-Met/Akt
and wnt pathway crosstalk in the surrounding cells. Strong
activation of the wnt pathway, which is also very important for
the normal intestinal stem cells, results in the conversion of the
differentiated cells into a more stem cell-like state [58,59].
Similarly, in glioblastoma, nitric oxide that is produced by the
tumor vasculature activates Notch signaling and induces the
expression of the stem cell marker nestin in the cells located in
the perivascular niche [60]. Induction of dedifferentiation by
inﬂammation or other environmental stimuli has also majorMutations
Epigeneti
c
ch
an
ge
s
ntiation
Fusion
ntiated 
Hybrid 
Cell
and 
sc 
ancer
ell
be viewed as the four major sources of tumor plasticity and heterogeneity during
f mature cells increases stemness and is believed to contribute to therapy resistance.
l fusion generates hybrid cells with both epithelial and immune cell-like properties.
hree small circles represent the three major inducers of tumor-plasticity. Mutations
ﬂammatory microenvironment are the most potent inducers of tumor cell plasticity.
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lation of antigens that are recognized by the immune system.
These tumors can evade from anti-tumor immune responses and
resist adoptive T cell therapies [61].
Dedifferentiation of fully differentiated cells is not uniquely
restricted to malignant cells, but upon damage or imbalance in tis-
sue homeostasis, also normal mature cells can reprogram into a
stem cell. In the airways epithelial stem cells reside at the basal
layer of the epithelium and produce multiple lineages of differen-
tiated cells. Ablation of these airway basal stem cells induces the
dedifferentiation of luminal secretory cells into stem cells that
are morphologically and functionally indistinguishable from the
original basal stem cells [62]. Similarly, radiation induced loss of
Lgr5+ cells in the intestinal crypts directs Dll+ secretory precursors
to regain stem cell properties and replenish Lgr5+ stem cells [63].
These ﬁndings suggest that a certain level of plasticity is required
to maintain normal tissue homeostasis and to activate and accom-
plish a proper regenerative program after injury. Most probably to
drive tumor initiation and progression cancer stem cells hijack
those mechanisms of the normal stem cells which they use to
restore tissue homeostasis. However, while dedifferentiation of
the normal tissue stem cells is a transient and most likely strictly
regulated process, in cancer stem cells these regulatory pathways
and checkpoints are missing or can be overcome. Therefore, by
studying regenerative responses in normal tissues we can possible
gain a better insight into tumor plasticity induced by
dedifferentiation.
Apart from dedifferentiation also transdifferentiation can be
observed during tumorigenesis (Fig. 2). Tissue metaplasia, a switch
from one tissue type to another tissues type, requires the transdif-
ferentiation of tissue cells. Intestinal metaplasia of the gastric epi-
thelium is one of the earliest steps in gastric cancer and
metaplastic lesions of the stomach develop into invasive cancer
via the metaplasia-dysplasia-carcinoma sequence. The most fre-
quent cause of intestinal metaplasia is Helicobacter pylori-induced
gastritis. It activates wnt/b-catenin signaling and induces the
expression of the homeobox transcription factor Cdx1, a master
regulator of the gut development and homeostasis, which under
physiological conditions is never expressed in the stomach [64].
Cdx1 expression in the stomach activates Klf5 and Sall4 repro-
gramming factors and leads to an increase in the intestinal stem
cell markers such as Lgr5 and Bmi1, suggesting that transdifferen-
tiation of gastric epithelial cells into intestinal-like cells occurs via
a more dedifferentiated state [65]. Besides the important ﬁnding
that transdifferentiation requires reprogramming these data also
pinpoint the fact that the whole process is induced by environmen-
tal stimuli. Microenvironmental factors, especially inﬂammation,
have been also shown to contribute to Barret esophagus (BE) and
esophageal adenocarcinoma (EAC). In BE the stratiﬁed epithelium
of the esophagus is replaced by metaplastic intestinal-like epithe-
lium, that may originate from Lgr5+ cardia cells which in response
to NF-jB-dependent cytokines, such as IL-6 and IL-1b, migrate up
to the esophagus and serve as cell of origin for BE and EAC [5].
Metaplasia or transdifferentiation also occurs in early stages of
pancreatic ductal adenocarcinoma (PDAC) development. Although
the cell of origin of pancreatic cancer has not been identiﬁed yet,
the requirement of acinar-to-ductal metaplasia (ADM) for PDAC
is well deﬁned. Activation of oncogenic K-Ras in combination with
Notch in mature acinar cells induces pronounced ADM which is
followed by the appearance of pancreatic intraepithelial lesions
[66]. Similar to intestinal metaplasia inﬂammation has a very pro-
found effect on ADM and pancreatic cancer and it is essential for
the induction of PDAC in adult mice [67]. One possibility how
inﬂammation contributes to ADM and subsequent PDAC is the
release in inﬂammatory cytokines by the inﬁltrating macrophages
and activation of NF-jB in the acinar cells [68]. In addition to that,within the process of malignant transformation pancreatic cells
not only elicit the production of growth factors, cytokines and
chemokines by the surrounding environment but they can, as a
consequence of transdifferentiation, comprise the main source of
those molecules [69].
Last but not least, fusion of cells of hematopoietic origin with
tumor cells could also signiﬁcantly contribute to tumor heteroge-
neity (Fig. 2). Fusion of macrophages with tumor cells of ApcMin
mice results in the formation of a new population of tumor cells
that share both macrophage- and tumor cell characteristics [70].
The fusion of the epithelial tumor cells with immune cells is
believed to confer a more stem cell-like and migratory phenotype
to the fusion-hybrid cells and therefore enhance the metastatic
spread of these cells [71,72].
4. Conclusions
In the last decade many new therapeutic strategies and sensi-
tive diagnostic tools have been developed to cure cancer. Despite
the efforts that have been made there is still an increasing number
of patients that succumb to this disease. Resistance to therapies
that occurs in most patients can be in part a consequence of tumor
plasticity. By changing their phenotype or by altering the microen-
vironment tumor cells can evade therapies. Therefore, a therapeu-
tic approach that blocks plasticity would be of great interest.
Inﬂammation represents a central regulator of tumor-associated
plasticity. Many examples have demonstrated that the NF-jB sig-
naling network is central to cancer-associated inﬂammation. NF-
jB signaling has roles both in the tumor-inﬁltrating cells and the
cancer cells themselves [73]. In inﬁltrating cells NF-jB signaling
promotes the production of inﬂammatory cytokines, many of
which have the potential to induce tumor cell plasticity either by
EMP or by reversing the cells to a less differentiated state
[38,61,74,75]. Therefore, NF-jB or its downstream target cytokines
and chemokines inducing and maintaining an pro-inﬂammatory
microenvironment may represent very powerful targets to inter-
fere with several aspects of tumor plasticity.
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